Early Briefing on Biotechnology Stocks — Achillion Pharma, CTI BioPharma, Inovio Pharma, and Keryx Biopharma

NEW YORK, NY / ACCESSWIRE / February 10, 2016 / Park Lane Advisor has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), CTI BioPharma Corporation (NASDAQ: CTIC), Inovio Pharmaceuticals Inc. (NASDAQ: INO), and Keryx Biopharmaceuticals Inc. (NASDAQ: KERX). Free note on Achillion Pharma can be accessed at http://www.parklaneadvisor.com/ On Tuesday, February 09, 2016, the NASDAQ Composite ended at 4,268.76, down 0.35%, the Dow Jones Industrial Average edged 0.08% lower, to finish the day at 16,014.38, and the S&P 500 closed at 1,852.21, down 0.07%. Register for your complimentary reports at the links given below.

Achillion Pharmaceuticals Inc.’s stock advanced 1.71%, to close the day at $5.96. The stock recorded a trading volume of 1.12 million shares, below its three months average volume of 2.10 million shares. The company’s shares are trading 31.03% below their 200-day moving average. Additionally, Achillion Pharmaceuticals Inc. has a Relative Strength Index (RSI) of 28.51. Sign up and read the free notes on ACHN at:

http://www.parklaneadvisor.com/

On Tuesday, shares in CTI BioPharma Corp. recorded a trading volume of 8.20 million shares, higher than their three months average volume of 1.87 million shares. The company’s stock surged 13.64%, to end the day at $0.50. The company is trading below its 50-day and 200-day moving averages by 57.40% and 68.39%, respectively. Furthermore, shares of CTI BioPharma Corp. have an RSI of 21.60. The complimentary notes on CTIC can be downloaded in PDF format at:

http://www.parklaneadvisor.com/

Inovio Pharmaceuticals Inc.’s stock finished Tuesday’s session 2.67% lower at $5.84. A total of 1.65 million shares were traded, which was below its three months average volume of 1.75 million shares. Inovio Pharmaceuticals Inc.’s shares have gained 1.39% in the last one month, but the stock has declined 13.22% over the previous three months. The company’s shares are trading below their 50-day and 200-day moving averages by 7.17% and 18.61%, respectively. Inovio Pharmaceuticals Inc.’s stock has an RSI of 48.04. Register for free on Park Lane Advisor and access the latest research on INO at:

http://www.parklaneadvisor.com/

On Tuesday, shares in Keryx Biopharmaceuticals Inc. ended the session 3.63% lower at $3.19. The stock reported a trading volume of 1.38 million shares, below its three months average volume of 1.66 million shares. The company is trading 26.79% below its 50-day moving average and 51.16% below its 200-day moving average. Moreover, shares of Keryx Biopharmaceuticals Inc. have an RSI of 39.77. The complete research on KERX is available for free at:

http://www.parklaneadvisor.com/

About Park Lane
Advisor:

Park Lane Advisor (“PLA”)
produces regular sponsored and non-sponsored reports, articles, stock market
blogs, and popular investment newsletters covering equities listed on NYSE and
NASDAQ and micro-cap stocks. PLA has two distinct and independent departments.
One department produces non-sponsored analyst certified content generally in
the form of press releases, articles and reports covering equities listed on
NYSE and NASDAQ and the other produces sponsored content (in most cases not
reviewed by a registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of procedures detailed
below.

PLA has not been compensated; directly or
indirectly; for producing or publishing this document.

PRESS RELEASE
PROCEDURES:

The non-sponsored content contained
herein has been prepared by a writer (the “Author”) and is fact
checked and reviewed by a third party research service company (the
“Reviewer”). The Reviewer has reviewed and revised the content, as
necessary, based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the Sponsor have
not performed any independent investigations or forensic audits to validate the
information herein. Unless otherwise noted, any content outside of this
document has no association with the Author, the Reviewer, or the Sponsor
(collectively referred to as the “Production Team”) in any way. The
Production Team is compensated on a fixed monthly basis and do not hold any
positions of interest in any of the securities mentioned herein.

NO
WARRANTY

PLA, the Author, the Reviewer and the
Sponsor (collectively referred to as the “Publishers”) are not
responsible for any error which may be occasioned at the time of printing of
this document or any error, mistake or shortcoming. No liability is accepted by
the Publishers whatsoever for any direct, indirect or consequential loss
arising from the use of this document. The Publishers expressly disclaim any
fiduciary responsibility or liability for any consequences, financial or
otherwise arising from any reliance placed on the information in this document.
Additionally, the Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2) warrant any
results from use of the information. The included information is subject to
change without notice.

NOT AN
OFFERING

This document is not intended as an
offering, recommendation, or a solicitation of an offer to buy or sell the
securities mentioned or discussed, and is to be used for informational purposes
only. Please read all associated disclosures and disclaimers in full before
investing. Neither PLA nor any party affiliated with us is a registered
investment adviser or broker-dealer with any agency or in any jurisdiction
whatsoever. To download our report(s), read our disclosures, or for more
information, visit www.ParkLaneAdvisor.com

RESTRICTIONS

PLA is not available to residents of
Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CONTACT

For any questions, inquiries, or comments
reach out to us directly at:

E-mail: media
(at) ParkLaneAdvisor (dot) com

SOURCE: Park
Lane Advisor

ReleaseID: 436675